The All Wales Medicines Strategy Group (AWMSG) has issued a Final Appraisal Recommendation on the use of collagenase Clostridium histolyticum (Xiapex®▼) for the treatment of the treatment of Dupuytren’s contracture in adult patients with a palpable cord within NHS Wales.

The Group recommends that treatment should be restricted for use as an alternative to fasciectomy in a subset of adult patients with a total of two or less affected joints per hand where percutaneous needle fasciotomy is not appropriate, using up to three injections per cord, with no more than six injections per patient. The Group was also of the opinion that collagenase Clostridium histolyticum is not suitable for shared care within NHS Wales for this indication.

Further information, including the assessment report, can be accessed via the link below.